Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 April 2019 | Story Valentino Ndaba | Photo Valentino Ndaba
Andrew Lane
Mining the fourth industrial revolution way is the future says industry expert, Andrew Lane.

Innovation is imperative for the future of mining in South Africa. Industry expert, Andrew Lane proposes that leveraging on new information, mining technologies and energy knowhow, which are the hallmarks of the fourth industrial revolution, should set the scene for success.

Lane who is Africa Energy and Resource Leader at Deloitte, engaged students at a recent guest lecture hosted by the University of the Free State’s Business School on the Bloemfontein Campus. “The future is intelligent mining. It’s not just about technology; it’s about changing the way you do business,” he said.

Transforming traditional to trailblazing
“What gives you sustainable competitive advantage is the rate at which you innovate,” said Lane. Design paradigm shifts in the South African mining industry may have resulted in about 100 000 job losses during the past four years. However, mining companies stand to achieve significant gains through applying innovation.

Despite most of South Africa’s mines nearing the end of their lives, mining remains a large employer and investor attractor which ensures that the country holds a competitive advantage in the global economy. Lane is adamant that, “even though we have declined from 20% to 5% in terms of GDP contributions, mining remains a large contributor to export earnings”.

Reaching resource-rich regions
While some physical resources are inaccessible using current technology, “new mineral-processing technologies help tap into previously uneconomical mineral deposits”, according to Lane. In addition to the environment, 3D visualisation cameras can track employees and equipment in the bowels of the earth.

More mining, less loss
Integrating mining, energy, and information technology will ensure that companies reduce people, capital and energy intensity, while increasing mining intensity. The impossible can be achieved if technology is used well for developmental outcomes, employment, and improving standards of living.



News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept